Introduction
============

Lung cancer is the most commonly diagnosed cancer worldwide, as well as the leading cause of cancer deaths. Worldwide in 2018, it accounted for 2.1 million new cases and 1.8 million deaths. Squamous cell carcinoma is one of the major well-studied histological subtypes of lung cancer  ([@ref-1]; [@ref-5]). However, basaloid squamous cell carcinoma of the lung (BSC), as a rare subtype of lung squamous cell carcinoma, is less studied, and the clinical features and prognostic factors remain unclear.

BSC is an uncommon histological variant of lung cancer composed of cells exhibiting cytological and tissue architectural features of both squamous cell lung carcinoma and basal cell carcinoma, while the proportion of squamous cell components is less than 50%  ([@ref-4]; [@ref-20]; [@ref-6]). It is reported that BSC accounts for 3.9%--5.2% of all lung squamous carcinomas and has unique clinical characteristics such as a high rate of metastasis and death, according to previous researches. Apart from this, BSC was once described with overlap features of large cell carcinoma (LCC) ([@ref-17]; [@ref-18]). Up to this date, no relevant literatures have reported the differences of clinical features with LCC and other non-small cell lung cancer (NSCLC). In this study, we compared clinicopathological characteristics of related lung cancer subtypes in detail, then we used univariate and Cox hazards regression analyses to identify risk factors affecting overall survival (OS) of BSC. We further developed a nomogram of patients with BSC based on the results of survival analysis to better predict the prognoses of patients.

Materials and Methods
=====================

Ethic statement
---------------

We obtained permission to use data files from the public database of the Surveillance, Epidemiology, and End Results (SEER) database. Thus, our research was exempted by the Ethics Committee of Suzhou Municipal Hospital.

Data extraction
---------------

Data of all primary pure basaloid squamous cell carcinoma patients (ICD-O-3: 8083/3) between 2004 to 2015 were identified by the SEER\*Stat software (v8.3.5, <https://seer.cancer.gov/seerstat/>) from the SEER database (<http://seer.cancer.gov/>). Exclusion criteria were: (1) pathological types of non-pure-type basaloid squamous cell carcinoma; (2) unknown aspects regarding differentiation, stage, and treatment methods; and (3) a history of tumors in other sites ([Fig. 1](#fig-1){ref-type="fig"}).

![The flow diagram of the selection process for the study cohort.](peerj-07-6724-g001){#fig-1}

We extracted and analyzed the data regarding patients' race, sex, age, grade, TMN stage, surgery type, radiotherapy, and chemotherapy. The total stage, T stage, N stage, and M stage of all patients were manually restaged according to the 8th edition of the American Joint Committee on Cancer (AJCC) lung cancer staging project.

Chi-square tests were used for comparison of multi-class variables like race between basaloid squamous cell carcinoma and other types of lung carcinomas. Rank sum tests were used for comparing two categorical variables or ordered variables. The quantitative variables of age were compared by the variance analysis method. In the analysis of prognostic factors for BSC, we used Kaplan--Meier analyses and log-rank tests for univariate analyses, and Cox model tests for multivariate analyses. The above analyses were performed using SPSS (version 25) software (SPSS, Chicago, IL, USA), all of which were two-sided tests, while *P* \< 0.05 was considered to be statistically significant. R language ([@ref-15]) was used to generate and validate the nomogram, while the main packages used were rms and Hmisc ([@ref-16]; [@ref-19]).

Results
=======

Comparison of clinical features between BSC and other types of NSCLC
--------------------------------------------------------------------

After screening, we enrolled 425 patients with BSC of pure type and 90006, 6997 and 160638 patients with SCC, LCC and LAC, respectively. Survival curves indicated that the survival of BSC patients was significantly better than those of SCC, LCC and LACpatients ([Fig. 2](#fig-2){ref-type="fig"} and [Fig. S1](#supp-1){ref-type="supplementary-material"}). As shown in [Table 1](#table-1){ref-type="table"}, 257 males and 168 females were included in the BSC group, with a median age of 70.15 years and interquartile range (IQR) of 59.87--80.43 years. In total, 358 (84.2%) were white. The grades included 0.5% grade I (well differentiated), 10.8% grade II (moderately differentiated), 64.5% grade III (poorly differentiated), and 3.0% grade IV (undifferentiated). Most BSC patients (42.1%) were AJCC stage I, 14.8% were stage II, 23.8% were stage III, and 19.3% were stage IV. BSC patients had significantly less well differentiated tumors (*P* \< 0.001), less N+ disease (*P* \< 0.001), fewer distant metastases (*P* \< 0.001), lower proportion of radiotherapy (*P* \< 0.001) and chemotherapy (*P* \< 0.001), but a higher percentage of radical surgical resection (*P* \< 0.001) than those of SCC and LAC patients. Conversely, only LCC patients had more undifferentiated tumors (*P* \< 0.001), while much lower proportion of surgery (*P* \< 0.001), radiotherapy (*P* \< 0.001) and chemotherapy (*P* \< 0.001) ([Table 1](#table-1){ref-type="table"}).

![Survival for BSC, SCC, LCC and LAC.\
The survival curves of basaloid squamous cell carcinoma of the lung (BSC), squamous cell carcinoma (SCC), large cell carcinoma (LCC) and lung adenocarcinoma (LAC).](peerj-07-6724-g002){#fig-2}
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###### Comparison of the clinipathological characteristics of basaloid squamous cell carcinoma (BSC), squamous cell carcinoma of the lung (SCC), large cell carcinoma of the lung (LCC) and lung adenocarcinoma (LAC).

![](peerj-07-6724-g005)

  **Characteristics**         BSC                    SCC                    *p* value   LCC                    *p* value   LAC                    *p* value
  --------------------------- ---------------------- ---------------------- ----------- ---------------------- ----------- ---------------------- -----------
  **Race, *n* (%)**                                                         0.351                              0.039                              0.049
  White                       358 (84.2)             75,272 (83.6)                      5,682 (81.2)                       128,685 (80.1)         
  Black                       43 (10.1)              10,617 (11.8)                      999 (14.3)                         18,644 (11.6)          
  Other                       24 (5.7)               4,117 (4.6)                        316 (4.5)                          13,309 (8.3)           
  **Age, median \[IQR\]**     70.15 (59.87--80.43)   70.41 (60.66--80.16)   0.139       67.92 (56.87--78.97)   0.303       68.37 (57.27--79.47)   0.376
  **Sex, *n* (%)**                                                          0.503                              0.443                              \<0.001
  Male                        257 (60.5)             55,849 (62.1)                      4,099 (58.6)                       78,527 (48.9)          
  Female                      168 (39.5)             34,157 (37.9)                      2,898 (41.4)                       82,111 (51.1)          
  **Grade, *n* (%)**                                                        \<0.001                            \<0.001                            \<0.001
  Well differetiated          2 (0.5)                1,974 (2.2)                        15 (0.2)                           11,955 (7.4)           
  Moderately differetiated    46 (10.8)              26,606 (29.6)                      80 (1.1)                           36,005 (22.4)          
  Poorly differetiated        274 (64.5)             32,307 (35.9)                      2,115 (30.2)                       43,291 (27.0)          
  Undifferetiated             13 (3.0)               648 (0.7)                          2,299 (32.9)                       968 (0.6)              
  Unknown                     90 (21.2)              28,471 (31.6)                      2,488 (35.6)                       68,419 (42.6)          
  **Total stage, *n* (%)**                                                  \<0.001                            \<0.001                            \<0.001
  I                           179 (42.1)             27,683 (30.8)                      1,460 (20.9)                       41,408 (25.8)          
  II                          63 (14.8)              10,946 (12.2)                      534 (7.6)                          10,560 (6.6)           
  III                         101 (23.8)             26,297 (29.2)                      1,858 (26.6)                       32,528 (20.2)          
  IV                          82 (19.3)              25,080 (27.8)                      3,145 (44.9)                       76,142 (47.4)          
  **T stage, *n* (%)**                                                      \<0.001                            \<0.001                            0.001
  T1                          133 (31.3)             9,151 (10.2)                       1,292 (10.2)                       43,558 (27.1)          
  T2                          139 (32.7)             66,275 (73.6)                      2,346 (73.6)                       47,776 (29.8)          
  T3                          68 (16.0)              3,596 (4.0)                        880 (4.0)                          22,072 (13.7)          
  T4                          85 (20.0)              10,984 (12.2)                      2,479 (12.2)                       47,232 (29.4)          
  **N stage, *n* (%)**                                                      \<0.001                            \<0.001                            \<0.001
  N0                          269 (63.3)             9,151 (10.2)                       2,847 (40.7)                       72,104 (44.9)          
  N1                          50 (11.8)              66,275 (73.6)                      663 (9.5)                          14,110 (8.8)           
  N2                          84 (19.8)              3,596 (4.0)                        2,628 (37.5)                       54,487 (33.9)          
  N3                          22 (5.1)               10,984 (12.2)                      859 (12.3)                         19,937 (12.4)          
  **M stage, *n* (%)**                                                      \<0.001                            \<0.001                            \<0.001
  M0                          343 (80.7)             58,972 (65.5)                      3,854 (55.1)                       84,496 (52.6)          
  M1                          82 (19.3)              31,034 (34.5)                      3,143 (44.9)                       76,142 (47.4)          
  **Surgery, *n* (%)**                                                      \<0.001                            \<0.001                            \<0.001
  Not performed               144 (33.9)             60,336 (67.0)                      5,041 (72.0)                       112,857 (70.3)         
  Lobectomy                   199 (46.8)             20,978 (23.3)                      1,377 (19.7)                       35,329 (22.0)          
  Sublobar resection          62 (14.6)              6,153 (6.8)                        438 (6.3)                          10,982 (6.8)           
  Pneumonectomy               20 (4.7)               2,539 (2.8)                        141 (2.0)                          1,470 (0.9)            
  **Radiotherapy, *n* (%)**                                                 \<0.001                            \<0.001                            \<0.001
  No                          104 (24.5)             4 (0.0)                            3,980 (56.9)                       98,823 (61.5)          
  Yes                         321 (75.5)             90,002 (100.0)                     3,017 (43.1)                       61,815 (38.5)          
  **Chemotherapy, *n* (%)**                                                 \<0.001                            \<0.001                            \<0.001
  No                          134 (31.5)             53,403 (59.3)                      3,944 (56.4)                       88,220 (54.9)          
  Yes                         291 (68.5)             36,603 (40.7)                      3,053 (43.6)                       72,418 (45.1)          

**Notes.**

*P* value for chi-square test.

BSCBasaloid squamous cell carcinomaSCCsquamous cell carcinomaLCClarge cell carcinoma of the lungLAClung adenocarcinomaIQRinterquartile range

Analyses of BSC prognostic factors
----------------------------------

We used univariate analyses to investigate possible prognostic factors in patients with BSC. As shown in [Table 1](#table-1){ref-type="table"}, there was a statistically significant correlation between age (*P* \< 0.001), grade (*P* \< 0.001), total stage (*P* \< 0.001), T stage (*P* \< 0.001), N stage (*P* \< 0.001), M stage (*P* \< 0.001), surgery (*P* \< 0.001), radiotherapy (*P* \< 0.001) and chemotherapy (*P* = 0.013) with prognoses of BSC. In other words, elder age, lower differentiation, and a higher total stage meant the worse prognosis. In addition, as shown in [Fig. 3A](#fig-3){ref-type="fig"}, univariate analyses showed that patients who underwent surgery had better prognoses than patients who did not, and were similar to patients receiving other surgical treatments (*P* \< 0.001). Particularly, the patients with Stage I to Stage IV who underwent lobectomy had better benefits than those undergoing sublobar resection ([Fig. 3B](#fig-3){ref-type="fig"}), including for total stage (*P* \< 0.0001), Stage I (*P* = 0.00016), Stage II (*P* = 0.0012), Stage III, and IV (both *P* = 0.03) ([Figs. 3C](#fig-3){ref-type="fig"}, [3D](#fig-3){ref-type="fig"} and [3E](#fig-3){ref-type="fig"}). Sex (*P* = 0.257) and race (*P* = 0.077) for the prognosis of BSC were not statistically significant ([Table 2](#table-2){ref-type="table"}).

![Survival for surgical modalities.\
(A) Survival analyses for patients with different surgeries and without surgery. (B) Survival analyses for patients with lobectomy and sublobar resection classified by tumor histology and tumor stage. (C) Stage I (1-, 3-, 5-year survival rate of lobectomy vs. sublobar section: 82.0%, 53.2%, 31.5% vs. 70.7%, 46.3%, 17.1%). (D) Stage II (1-, 3-, 5-year survival rate of lobectomy vs. sublobar section: 71.1%, 40.0%, 31.1% vs. 75.0%, 12.5%, 12.5%). (E) Stage III and IV (1-, 3-, 5-year survival rate of lobectomy vs. sublobar section: 67.4%, 32.6%, 18.6% vs. 46.2%, 7.7%, 0.0%).](peerj-07-6724-g003){#fig-3}
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###### Univariate and multivariate Cox proportional hazards analysis.

![](peerj-07-6724-g006)

  Patient characteristics    Univariate analysis    Multivariate analysis                           
  -------------------------- ---------------------- ----------------------- ----------------------- ---------
  **Race**                                          0.077                                           --
  White                      Reference                                      --                      --
  Black                      1.251 (0.811--1.931)   0.311                   --                      --
  Other                      0.502 (0.248--1.019)   0.056                   --                      --
  **Age**                                           \<0.001                 1.032 (1.017--1.048)    \<0.001
  **Sex**                                           0.257                                           --
  Male                       Reference                                      --                      --
  Female                     0.855 (0.652--1.121)                           --                      --
  **Grade**                                         \<0.001                                         0.248
  Well differetiated         Reference                                      Reference               
  Moderately differetiated   0.776 (0.181--3.322)   0.733                   2.179 (0.404--11.756)   0.365
  Poorly differetiated       0.994 (0.245--4.033)   0.993                   1.894 (0.369--9.712)    0.444
  Undifferetiated            1.748 (0.375--8.139)   0.477                   4.198 (0.689--25.591)   0.120
  Unknown                    2.291 (0.537--9.421)   0.251                   2.101 (0.401--10.988)   0.379
  **AJCC 8thT stage**                               \<0.001                                         \<0.001
  T1                         Reference                                      Reference               
  T2                         1.052 (0.735--1.507)   0.780                   1.240 (0.856--1.797)    0.256
  T3                         1.909 (1.274--2.862)   0.002                   1.935 (1.257--2.980)    0.003
  T4                         2.689 (1.879--3.849)   \<0.001                 2.364 (1.559--3.585)    \<0.001
  **AJCC 8thN stage**                               \<0.001                                         0.009
  N0                         Reference                                      Reference               
  N1                         1.678 (1.088--2.587)   0.019                   1.623 (1.018--2.586)    0.042
  N2                         3.218 (2.360--4.390)   \<0.001                 1.905 (1.300--2.792)    0.001
  N3                         5.013 (2.855--8.804)   \<0.001                 1.826 (0.951--3.505)    0.071
  **AJCC 8thM stage**                               \<0.001                                         \<0.001
  M0                         Reference                                      Reference               
  M1                         4.253 (3.170--5.704)   \<0.001                 2.399 (1.695--3.393)    \<0.001
  **Surgery**                                       \<0.001                                         \<0.001
  Not performed              Reference                                      Reference               
  Lobectomy                  0.187 (0.136--0.258)   \<0.001                 0.389 (0.263--0.578)    \<0.001
  Sublobar resection         0.442 (0.304--0.643)   \<0.001                 0.889 (0.567--1.394)    0.608
  Pneumonectomy              0.384 (0.209--0.706)   \<0.001                 0.614 (0.317--1.189)    0.148
  **Radiotherapy**                                  \<0.001                                         
  No                         Reference                                      Reference               
  Yes                        2.173 (1.631--2.895)   \<0.001                 1.076 (0.768--1.508)    0.669
  **Chemotherapy**                                                                                  
  No                         Reference                                      Reference               
  Yes                        1.423 (1.076--1.882)   0.013                   0.725 (0.506--1.039)    0.080

**Notes.**

\**P* value for chi-square test. *C*-index = 0.750.

The total stage was not an independent variable related to T, N, and M stage, therefore it was excluded in the multivariate analysis.

The data revealed that the factors of age (*P* \< 0.001), T stage (*P* \< 0.001), N stage (*P* = 0.009), M stage (*P* \< 0.001), and surgery (*P* \< 0.001) with statistical significance using univariate analysis were found to be independent factors according to multivariate analyses ([Table 2](#table-2){ref-type="table"}). Multivariate analyses revealed that the older patient and the higher the TMN stage, the worse the prognosis. Excluding the significant effects of T3 (*P* = 0.003), T4 (*P* \< 0.001) and N2 (*P* = 0.001), the remaining T stage and N stage of the prognoses of patients were similar. Compared with T1 and N0, the odds ratios (ORs) were T2: 1.240 (0.856--1.797), T3: 1.935 (1.257--2.980), T4: 2.364 (1.559--3.585), and N1: 1.623 (1.018--2.586), N2: 1.905 (1.300--2.792), and N3: 1.826 (0.951--3.505), respectively. The prognoses of patients undergoing lobectomy were significantly better than other surgical styles, with an OR of 0.389 (0.263--0.578) compared with nonsurgical or other surgical patients. Unlike the results of univariate analysis, multivariate analysis showed that radiotherapy and chemotherapy were not independent prognostic factors.

Production and inspection of the nomogram
-----------------------------------------

We successfully constructed a nomogram based on the above independent predictors of patient outcomes ([Fig. 4A](#fig-4){ref-type="fig"}). According to the patients' age, T stage, N stage, M stage, and surgery, we visually calculated the patient's 1- ([Fig. 4B](#fig-4){ref-type="fig"}), 3- ([Fig. 4C](#fig-4){ref-type="fig"}) and 5-year ([Fig. 4D](#fig-4){ref-type="fig"}) survival probabilities. The *C*-index of this nomogram was 0.750 as determined by the discriminant test. The consistency test showed that the 3-year and 5-year survival rates predicted by the nomogram were in good agreement with the actual 3-year and 5-year survival rates, and the slope of the consistency curve was close to 1.

![Nomogram and overall survival nomogram calibration curves.\
(A) Nomogram for prediction of 1-, 3- and 5- year overall survival of patients with basaloid squamous cell carcinoma of the lung (BSC). Calibration plots of the nomogram prediction of (B) 1-year, (C) 3-year and (D) 5-year overall survival nomogram calibration curves. The red line represents equality of the observed and predicted probability.](peerj-07-6724-g004){#fig-4}

Discussion
==========

We conducted an in-depth analysis of BSC using the patients' data from the SEER database and we found that there were significant statistical differences with SCC, LCC and LAC in terms of race, grade, total stage, T stage, N stage, M stage, surgery, radiotherapy and chemotherapy. We also found that age, T stage, N stage, M stage and surgery were independent influencing factors for the prognoses of patients with BSC. We then plotted a nomogram. Consistency detection proved that the nomogram effectively predicted the 1-, 3- and 5-year survival probabilities of patients, while the nomogram scores effectively discriminated the patients' survivals.

BSC is an invasive subtype of squamous cell carcinoma that can be detected in the proximal bronchi ([@ref-20]; [@ref-10]). Unlike other previous studies ([@ref-3]), we verified that the prognosis of BSC was better than SCC, LCC and LAC. In this study, we found that the prognosis of BSC in a population-based cohort was better than SCC, LCC, and LAC. However, there are some previous studies reported opposite results to ours ([@ref-2]; [@ref-14]), perhaps due to that the number of cases varied, and most of other studies focused on the patients with surgery. Meanwhile, BSC has a significant lower TNM stage than other lung cancers according to our results.

In this population-based study, BSC and other types of lung cancers had similarities in terms of age. But [@ref-14] reported that BSC patients are older than non-BSC patients. Thus, [@ref-20] demonstrated that there was no significant statistical difference of mean age between BSC (58.6 years) and poorly differentiated squamous cell carcinoma (60.5 years) (*P* = 0.363).There were more patients with poorly differentiated BSCs, while the numbers of patients of N^+^ and M^+^ were less than those with SCC, LCC and LAC. In our study, the 5-year survival rate of the BSC patients was close to 17.6%. In other reports, the 5-year survival rate for BSC of stage I and stage II was less than 15%, much lower than the 5-year survival rate of 47% for resectable poorly differentiated SCC ([@ref-13]). However, [@ref-10] reported that there was no significant difference in the median survival rate between BSC and SCC in patients with stage I, without lymph node metastasis. Moreover, [@ref-14] reported that operative modes had no difference between the prognosis of BSC and poorly-differentiated SCC. As shown in the [Fig. S2](#supp-2){ref-type="supplementary-material"}, we compared the differences between the two groups by utilizing the survival curve. It clearly indicated that poorly-differentiated BSCs had better 5-year prognosis than poorly-differentiated SCCs, which were similar to the overall comparison results of this research. [@ref-20] also revealed that BSC and poorly differentiated squamous cell carcinomas had very similar clinical features, and there were no significant differences in survival rates, while in our results the survival of poorly differentiated BSC was superior to that of SCC with the same differentiation. More research should be carried out to validate the results.

Currently, surgery is the best curative treatment in stage I, stage II, and some stage III non-small lung cancers ([@ref-11]). Thus, lobectomy is still recommended as a preferred treatment for BSC, while more patients with peripheral tumors have undergone sublobar section  ([@ref-28]). However, both in our univariate analyses and multivariate analyses, patients with lobectomy had a better prognosis than patients undergoing other therapies. Our results also suggested that at any stage, even stage III and IV, the prognosis of patients with lobectomy was significantly better than those with sublobar section. This may due to the radical lobectomy that reduces the potential risks for relapse and distant metastases of solid tumors  ([@ref-21]). In addition, survival following sublobar section was inferior to lobectomy for stage I non-small cell lung cancer  ([@ref-29]). Therefore, further studies with larger cohorts, between lobectomy and sublobar section, especially when classified by histology, should be performed.

Nomogram, as an easily available and measurable tool of statistical prediction, which provides prognostic probability of specific outcomes ([@ref-9]; [@ref-27]). So far, multiple nomograms have been constructed for predicting prognosis of different types of lung cancers ([@ref-30]; [@ref-26]; [@ref-25]). Thus, it has even been considered more applied than the traditional AJCC TNM staging system in diverse malignancies according to great quantity of previous evidence ([@ref-12]; [@ref-22]). Furthermore, nomograms are especially advisable to deal with individual patients without existing definite clinical guidelines. In general, it seems simple and convenient via utilizing nomograms to predict patients' long-time survival according to their own characteristic.

The latest National Comprehensive Cancer Network recommends that *EGFR* mutations and other gene mutations should be considered as markers for lung squamous cell carcinoma, especially for non-smokers, small biopsy, or mixed squamous cell carcinoma  ([@ref-8]; [@ref-7]). Although the gene mutation status has not been well investigated in BSC, a molecularly targeted treatment may still have great potential to be used in the treatment for BSC.

The SEER database is a population-based tumor epidemiology database in the United States, covering about 28% of the population, including thousands of cases of lung cancers since 1973, therefore the SEER database is of great help in the study of lung cancer and other tumors  ([@ref-23]; [@ref-24]). By analyzing the cases in the entire population of the SEER database, it is possible to effectively avoid the bias of the patients from the research given by a single institution. Nevertheless, there is often a lack of imaging data, smoking history, gene mutations, tumor markers, and data regarding other detailed treatments, especially chemotherapy regimens in the SEER database. Therefore, the impact of these factors on the prognoses of patients with BSC was not included in our study. These factors may significantly affect the prognoses of the patients.

In our study, we have selected BSC cases that met the requirements as much as possible. But there was still a significant gap with the number of SCC. Though there seemed to be some controversy, it was still determined by its specific characteristics. We should further pay close attention to the future prognosis of BSCs. We acknowledge that the article limited the findings to epidemiological analysis and did not set more emphasis on exploring the biology of rare tumors such as molecular mechanism for gene therapy strategy.

Conclusion
==========

BSC has unique clinical and prognostic features that differ from SCC, LCC and LAC. Age, T stage, N stage, M stage and surgery were found to be independent predictors of prognoses in patients with BSC. The nomogram we constructed better predicted the patients' 1-, 3-, and 5-year survival probabilities.
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###### The survival curve between BSC and other types of lung cancers

\(A\) The survival curve of basaloid squamous cell carcinoma of the lung (BSC) and lung squamous cell carcinoma (SCC). (B) The survival curve of basaloid squamous cell carcinoma of the lung (BSC) and large cell carcinoma (LCC). (C) The survival curve of basaloid squamous cell carcinoma of the lung (BSC) and lung adenocarcinoma (LAC).

###### 

Click here for additional data file.
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###### The survival curve of PBSC and PSCC

The survival curve of poor differentiated basaloid squamous cell carcinoma of the lung (PBSC) and poor differentiated lung squamous cell carcinoma (PSCC).

###### 

Click here for additional data file.
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###### The raw data of clinipathological characteristics of BSC

###### 

Click here for additional data file.
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###### The raw data of clinipathological characteristics of SCC

###### 

Click here for additional data file.
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###### The raw data of clinipathological characteristics of LCC

###### 

Click here for additional data file.
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###### The raw data of clinipathological characteristics of LAC

###### 

Click here for additional data file.
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